Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Total Non-Current Liabilities (2022 - 2024)

Mangoceuticals' Total Non-Current Liabilities history spans 3 years, with the latest figure at $12167.0 for Q3 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 85.07% to $12167.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $12167.0, a 85.07% decrease, with the full-year FY2023 number at $64961.0, down 49.52% from a year prior.
  • Total Non-Current Liabilities hit $12167.0 in Q3 2024 for Mangoceuticals, down from $30117.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for MGRX hit a ceiling of $128680.0 in Q4 2022 and a floor of $12167.0 in Q3 2024.
  • Historically, Total Non-Current Liabilities has averaged $71975.5 across 3 years, with a median of $73234.5 in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 49.52% in 2023 and later tumbled 85.07% in 2024.
  • Tracing MGRX's Total Non-Current Liabilities over 3 years: stood at $128680.0 in 2022, then crashed by 49.52% to $64961.0 in 2023, then plummeted by 81.27% to $12167.0 in 2024.
  • Business Quant data shows Total Non-Current Liabilities for MGRX at $12167.0 in Q3 2024, $30117.0 in Q2 2024, and $47713.0 in Q1 2024.